Dow : On October 26, 2022, the Company completed the offering of the Notes - Form 8-K

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 26, 2022 (October 24, 2022)

Commission File Number		Exact Name of Registrant as Specified in its Charter, Principal Office Address and Telephone Number		State of Incorporation or Organization		I.R.S. Employer Identification No.
001-38646		Dow Inc. 2211 H.H. Dow Way, Midland, MI 48674 (989) 636-1000		Delaware		30-1128146
001-03433		The Dow Chemical Company 2211 H.H. Dow Way, Midland, MI48674 (989) 636-1000		Delaware		38-1285128

Check the appropriate box below if the Form

8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Registrant		Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Dow Inc.		Common Stock, par value $0.01 per share		DOW		New York Stock Exchange
The Dow Chemical Company		0.500% Notes due March 15, 2027		DOW/27		New York Stock Exchange
The Dow Chemical Company		1.125% Notes due March 15, 2032		DOW/32		New York Stock Exchange
The Dow Chemical Company		1.875% Notes due March 15, 2040		DOW/40		New York Stock Exchange
The Dow Chemical Company		4.625% Notes due October 1, 2044		DOW/44		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule

12b-2

of the Securities Exchange Act of 1934

(§240.12b-2

of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 8.01. Other Events.

On October 24, 2022, The Dow Chemical Company, a Delaware corporation (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with Citigroup Global Markets Inc., BofA Securities, Inc., HSBC Securities (USA) Inc. and Mizuho Securities USA LLC, as representatives of the several underwriters named in Schedule I thereto (collectively, the "Underwriters"), pursuant to which the Company agreed to issue and sell to the Underwriters $1.5 billion in aggregate principal amount of notes, consisting of $600,000,000 aggregate principal amount of 6.300% Notes due 2033 (the "2033 Notes") and $900,000,000 aggregate principal amount of 6.900% Notes due 2053 (the "2053 Notes", and together with the 2033 Notes, the "Notes"). The Notes were offered and issued pursuant to the Company's registration statement on Form

S-3

(File

No. 333-265556-01),

filed with the Securities and Exchange Commission on June 13, 2022.

In connection with the offering of the Notes, the Company is filing a copy of the Underwriting Agreement attached as Exhibit 1.1 to this Current Report on Form

8-K

and incorporated herein by reference.

On October 26, 2022, the Company completed the offering of the Notes.

The Notes were issued under an Indenture dated as of July 26, 2019 (the "Indenture"), among the Company, Dow Inc., as a party with respect to the sections described therein, and The Bank of New York Mellon Trust Company, N.A., as trustee.

In connection with the offering of the Notes, the Company is filing a legal opinion by counsel regarding the validity of the Notes, attached as Exhibit 5.1 to this Current Report on Form

8-K.

The foregoing descriptions of the Underwriting Agreement, the Indenture and the Notes are summaries and are qualified in their entirety by reference to such documents, which are attached as Exhibits 1.1, 4.1, 4.2, and 4.3 to this Current Report on Form

8-K,

respectively, and all of which are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
1.1*		Underwriting Agreement, dated as of October 24, 2022, among The Dow Chemical Company and the several underwriters named therein.
4.1		Indenture dated as of July 26, 2019, between The Dow Chemical Company, Dow Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.3 to the Company's Annual Report on Form10-K, filed on February 7, 2020 and incorporated herein by reference).
4.2*		Form of 6.300% Notes due 2033.
4.3*		Form of 6.900% Notes due 2053.
5.1*		Opinion dated October 26, 2022 of Shearman & Sterling LLP.
23.1*		Consent of Shearman & Sterling LLP (included in Exhibit 5.1).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

*	Documents filed with this report.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DOW INC.
THE DOW CHEMICAL COMPANY
Dated: October 26, 2022
By:		/s/ RONALD C. EDMONDS
	Ronald C. Edmonds
	Controller and Vice President of Controllers and Tax